Provided By PR Newswire
Last update: Sep 10, 2025
NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi).
Read more at prnewswire.comNASDAQ:HOTH (10/1/2025, 9:58:06 AM)
1.62
0 (0%)
Find more stocks in the Stock Screener